2024
Neutralizing antibodies after nebulized phage therapy in cystic fibrosis patients
Bernabéu-Gimeno M, Pardo-Freire M, Chan B, Turner P, Gil-Brusola A, Pérez-Tarazona S, Carrasco-Hernández L, Quintana-Gallego E, Domingo-Calap P. Neutralizing antibodies after nebulized phage therapy in cystic fibrosis patients. Med 2024, 5: 1096-1111.e6. PMID: 38917792, DOI: 10.1016/j.medj.2024.05.017.Peer-Reviewed Original ResearchMulti-drug resistanceCystic fibrosis patientsPhage therapyClinical outcomesLung infectionFibrosis patientsCystic fibrosisPseudomonas aeruginosa lung infectionAnti-phage antibodiesImmune responseStandard-of-care antibioticsInvasive routes of administrationPhage-neutralizing antibodiesBacterial loadBacterial lung infectionsCystic Fibrosis FoundationNo adverse eventsRoute of administrationPhage preparationsEmergence of antibodiesPhage detectionAntibiotic susceptibilityPhageStaphylococcus aureusBacterial eradication
2022
1432. Exploring Cell Wall Targets to Overcome Mycobacterium tuberculosis (Mtb): Ceftriaxone (CRO) Inhibits LdtMt2, a Major Peptidoglycan (PG) Synthase
Nguyen D, Redmond S, Dousa K, Bethel C, Taracila M, Li Q, Kurz S, Pavelka M, Papp-Wallace K, Holland S, Kreiswirth B, Boom H, Bonomo R. 1432. Exploring Cell Wall Targets to Overcome Mycobacterium tuberculosis (Mtb): Ceftriaxone (CRO) Inhibits LdtMt2, a Major Peptidoglycan (PG) Synthase. Open Forum Infectious Diseases 2022, 9: ofac492.1261. PMCID: PMC9752925, DOI: 10.1093/ofid/ofac492.1261.Peer-Reviewed Original ResearchDrug-resistant tuberculosisB-lactamaseMTB isolatesDifficult-to-treat infectionsB-lactamase inhibitorsFractional inhibitory concentration indexMultidrug-resistant mycobacteriaIn vitro susceptibilityCystic Fibrosis FoundationBroth microdilution methodPG synthasesElectrospray ionization-mass spectrometryCeftriaxone MICsDR-TBSusceptibility testingImipenemMeropenemTB guidelinesCeftriaxoneB-lactamTreatment strategiesClinical studiesLowered MICClavulanateMicrodilution method
2020
Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Disease 2019
Wagner D, Ikonomou L, Gilpin S, Magin C, Cruz F, Greaney A, Magnusson M, Chen Y, Davis B, Vanuytsel K, Enes S, Krasnodembskaya A, Lehmann M, Westergren-Thorsson G, Stegmayr J, Alsafadi H, Hoffman E, Weiss D, Ryan A. Stem Cells, Cell Therapies, and Bioengineering in Lung Biology and Disease 2019. ERJ Open Research 2020, 6: 00123-2020. PMID: 33123557, PMCID: PMC7569162, DOI: 10.1183/23120541.00123-2020.Peer-Reviewed Original ResearchCell therapyProgenitor cellsLung stemLung biologyInduced pluripotent stem cell modelsInternational Society for CellTreatment of lung diseasesPluripotent stem cell modelsPulmonary Fibrosis FoundationCystic Fibrosis FoundationStem cell modelRegenerative medicine productsAlpha-1 FoundationUniversity of Vermont Larner College of MedicineGene therapyCystic fibrosisLung diseaseCollege of MedicineTherapyStem cellsAlpha 1LungBlood InstituteNational HeartExtracellular vesicles
2018
Ozone disinfection of home nebulizers effectively kills common cystic fibrosis bacterial pathogens
Towle D, Baker V, Schramm C, O'Brien M, Collins MS, Feinn R, Murray TS. Ozone disinfection of home nebulizers effectively kills common cystic fibrosis bacterial pathogens. Pediatric Pulmonology 2018, 53: 599-604. PMID: 29542874, DOI: 10.1002/ppul.23990.Peer-Reviewed Original ResearchConceptsHome respiratory equipmentCystic Fibrosis FoundationNebulizer outputRespiratory equipmentBacterial pathogensCommon bacterial pathogensOzone exposureHome nebulizersNebulizer functionInfusion timeNebulizer equipmentJet nebulizerMin infusion timeHome careStaphylococcus aureusBacterial recoveryPseudomonas aeruginosaExposureHeavy burdenGross changesNebulizerPathogensSeparate experiments
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply